The average one-year price target for Sensorion (ENXTPA:ALSEN) has been revised to €2.14 / share. This is an increase of 12.00% from the prior estimate of €1.91 dated July 15, 2025.

The price target is an average of many targets provided by analysts. The latest targets range from a low of €1.01 to a high of €3.15 / share. The average price target represents an increase of 569.38% from the latest reported closing price of €0.32 / share.

What is the Fund Sentiment?

There are 6 funds or institutions reporting positions in Sensorion. This is an increase of 2 owner(s) or 50.00% in the last quarter. Average portfolio weight of all funds dedicated to ALSEN is 0.08%, an increase of 34.18%. Total shares owned by institutions increased in the last three months by 49.74% to 31,062K shares.

What are Other Shareholders Doing?

FBIOX - Biotechnology Portfolio holds 20,084K shares representing 6.68% ownership of the company. In its prior filing, the firm reported owning 20,279K shares , representing a decrease of 0.97%. The firm decreased its portfolio allocation in ALSEN by 15.63% over the last quarter.

PRHSX - T. Rowe Price Health Sciences Fund holds 10,027K shares representing 3.34% ownership of the company.

QAAGZX - T. Rowe Price Health Sciences Portfolio holds 486K shares representing 0.16% ownership of the company.

JAFMX - Health Sciences Trust NAV holds 183K shares representing 0.06% ownership of the company. No change in the last quarter.

John Hancock Funds II - Health Sciences Fund Class NAV holds 156K shares representing 0.05% ownership of the company. In its prior filing, the firm reported owning 182K shares , representing a decrease of 16.72%. The firm increased its portfolio allocation in ALSEN by 75.76% over the last quarter.